Meridian Bioscience (NASDAQ: VIVO) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its rivals? We will compare Meridian Bioscience to similar businesses based on the strength of its risk, valuation, analyst recommendations, earnings, profitability, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations for Meridian Bioscience and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Meridian Bioscience 1 3 0 0 1.75
Meridian Bioscience Competitors 174 1133 2482 89 2.64

Meridian Bioscience presently has a consensus price target of $14.00, suggesting a potential downside of 11.39%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 8.65%. Given Meridian Bioscience’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Meridian Bioscience has less favorable growth aspects than its rivals.

Profitability

This table compares Meridian Bioscience and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Meridian Bioscience 0.48% 0.57% 0.39%
Meridian Bioscience Competitors -127.32% -36.61% -10.40%

Institutional and Insider Ownership

87.3% of Meridian Bioscience shares are held by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 2.3% of Meridian Bioscience shares are held by insiders. Comparatively, 11.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Meridian Bioscience and its rivals revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Meridian Bioscience $198.07 million $52.80 million 30.98
Meridian Bioscience Competitors $827.23 million $159.49 million 36.89

Meridian Bioscience’s rivals have higher revenue and earnings than Meridian Bioscience. Meridian Bioscience is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Meridian Bioscience has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Meridian Bioscience’s rivals have a beta of 1.06, indicating that their average share price is 6% more volatile than the S&P 500.

Dividends

Meridian Bioscience pays an annual dividend of $0.50 per share and has a dividend yield of 3.2%. Meridian Bioscience pays out 98.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Medical Equipment, Supplies & Distribution” companies pay a dividend yield of 0.8% and pay out 37.4% of their earnings in the form of a dividend.

Summary

Meridian Bioscience rivals beat Meridian Bioscience on 10 of the 15 factors compared.

About Meridian Bioscience

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

Receive News & Stock Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related stocks with our FREE daily email newsletter.